Quantcast

Industry news that matters to you.  Learn more

Cytokine Antibody Array Assays Developed by RayBiotech, Inc. Used to Identify Key Cancer Cell Chemoresistance Pathway

Reading time: 1 – 2 minutes

RayBiotech, Inc. announced today that several antibody-based biomarker screening assays developed by the company were utilized to identify a critical pathway involved in chemotherapeutic resistance acquired by melanoma cancer cells.

Specifically, the RayBio┬« G-Series 4000 and the RayBio┬« L-Series 507 cytokine antibody arrays allowed the characterization of a specific pathway associated with the cancer cells’ ability to develop resistance to chemotherapeutic agents. Utilizing RayBiotech’s antibody arrays, the authors discerned that the microenvironment of a melanoma tumor plays a crucial role in modulating resistance to certain cancer drugs. In addition, the arrays helped to identify individual factors acting upon cancer cells that are both necessary and sufficient to drive chemoresistance. These studies revealed unique biochemical and molecular targets for possible therapeutic intervention for the treatment and management of melanoma. The seminal research was published in Nature (Nature. 2012 Jul 26; 487:500-4).

Commenting on the research, RayBiotech’s President and Chief Operating Officer Rani Huang stated, “The findings of this research have comprehensively outlined a novel mechanism behind the acquisition of chemoresistance by one of the deadliest forms of cancer. We are pleased that RayBiotech’s antibody arrays played important roles in chemoresistance pathway characterization. This is a perfect example of how our high-content screening tools can facilitate potential drug target identification.”

Study: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Source: Market Wire